The Eiger Biopharmaceuticals Inc (EIGR) Receives “Buy” Rating from Jefferies Group LLC

The Eiger Biopharmaceuticals Inc (EIGR) Receives “Buy” Rating from Jefferies Group LLC

Several other analysts also recently commented on EIGR. Zacks Investment Research raised shares of Eiger Biopharmaceuticals from a hold rating to a strong-buy rating and set a $12.00 price objective on the stock in a report on Tuesday, March 28th. Piper Jaffray Companies set a $36.00 price objective on shares of Eiger Biopharmaceuticals and gave the company a buy rating in a report on Saturday, April 8th. Finally, Oppenheimer Holdings Inc. set a $34.00 price objective on shares of Eiger Biopharmaceuticals and gave the company a buy rating in a report on Saturday, April 8th. Five investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and a consensus target price of $28.15.

Jefferies Group LLC restated their buy rating on shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) in a report issued on Monday, May 15th. They currently have a $27.00 price target on the biotechnology company’s stock, down from their previous price target of $28.00.

Shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) opened at 6.95 on Monday. Eiger Biopharmaceuticals has a one year low of $6.57 and a one year high of $23.10. The firm’s 50-day moving average is $7.46 and its 200-day moving average is $10.48. The company’s market cap is $58.15 million. Eiger Biopharmaceuticals (NASDAQ:EIGR) last issued its quarterly earnings results on Friday, May 12th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.35) by $0.01. On average, equities analysts anticipate that Eiger Biopharmaceuticals will post ($5.84) EPS for the current year.

A number of hedge funds have recently made changes to their positions in the company. Sphera Funds Management LTD. increased its stake in shares of Eiger Biopharmaceuticals by 147.9% in the third quarter. Sphera Funds Management LTD. now owns 373,568 shares of the biotechnology company’s stock worth $5,002,000 after buying an additional 222,852 shares during the period. Interwest Venture Management Co. purchased a new stake in shares of Eiger Biopharmaceuticals during the fourth quarter worth about $18,635,000. Hikari Power Ltd purchased a new stake in shares of Eiger Biopharmaceuticals during the first quarter worth about $118,000. Perceptive Advisors LLC purchased a new stake in shares of Eiger Biopharmaceuticals during the fourth quarter worth about $1,836,000. Finally, RA Capital Management LLC boosted its position in Eiger Biopharmaceuticals by 21.4% in the third quarter. RA Capital Management LLC now owns 354,200 shares of the biotechnology company’s stock worth $4,743,000 after buying an additional 62,500 shares in the last quarter. 53.89% of the stock is currently owned by hedge funds and other institutional investors. About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:EIGR”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment